预约演示

更新于：2025-07-02

Fluorouracil

氟尿嘧啶

更新于：2025-07-02

概要

基本信息

药物类型

小分子化药

别名

5-fluoro-1H-pyrimidine-2,4-dione、5-Fluoropyrimidine-2,4-dione、5-Fluorouracil

+ [36]

靶点

TYMS

作用方式

抑制剂

作用机制

TYMS抑制剂(胸苷酸合成酶抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [10]

在研适应症

食管癌肠肿瘤头颈部肿瘤+ [97]

非在研适应症

胆道腺癌转移性腺癌晚期胆道癌+ [111]

原研机构

Spectrum Pharmaceuticals, Inc.

在研机构

NRG Oncology

National Cancer Institute

Alliance for Clinical Trials in Oncology

+ [26]

非在研机构

NYU Langone HealthHoffmann-La Roche, Inc.

Sanofi

+ [42]

权益机构

皮尔法伯（上海）医疗科技有限公司

Hill Dermaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1962-04-25),

乳腺癌结直肠癌胰腺癌+ [1]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C4H3FN2O2

InChIKeyGHASVSINZRGABV-UHFFFAOYSA-N

CAS号51-21-8

关联

2,619

项与氟尿嘧啶相关的临床试验

NCT07041749

/ Not yet recruitingN/AIIT

Comparison of the Efficacy of Microneedling Alone Versus Microneedling Coupled With Either Bleomycin or 5flourouracil in the Treatment of Plantar Warts

To compare between the efficacy and safety of microneedling alone, microneedling with topical bleomycin and microneedling with 5-flurouracil in treatment of planter warts.
Microneedling will be performed on each wart using dermapen supplied with 12 needles arranged in rows. Topical anesthetic cream will be applied for 60 min before the procedures. Microneedling will be performed on each wart using dermapen. The penetration depth will be adjusted at 2-mm, endpoint is pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the warts.
Bleomycin is typically supplied in 15 U vials. The preparation will be diluted first with 7 mL normal saline ,double the amount taken from the vial by adding the same amount lidocaine (2%), so that the concentrations become 1 U/mL . The maximum total amount of bleomycin taken to each patient in one session will be 1 U/1 mL . Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of the prepared solution of bleomycin (1 U/1 mL) will be dropped on to the wart tissue using insulin syringe and occlusion will be applied for 3 hours.
5-FU is available in 10 mL vial: 500 mg/10 mL. Application of 5-FU solution will be done by dropping using an insulin syringe (1 mL)to help dropping of the solution on the warts surface. Then, the lesion will be occluded with a plaster for 3 h.
Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)

开始日期2026-06-01

申办/合作机构

Assiut University

NCT06696768

/ Recruiting临床1期IIT

Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer

This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.

开始日期2026-01-23

申办/合作机构

National Cancer Institute

NCT06998940

/ Not yet recruiting临床3期IIT

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

开始日期2026-01-06

申办/合作机构

SWOG

[+1]

100 项与氟尿嘧啶相关的临床结果

登录后查看更多信息

100 项与氟尿嘧啶相关的转化医学

登录后查看更多信息

100 项与氟尿嘧啶相关的专利（医药）

登录后查看更多信息

74,679

项与氟尿嘧啶相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients

Article

作者: Sirilerttrakul, Suwannee ; Sukasem, Chonlaphat ; Sankuntaw, Nipaporn ; Satapornpong, Patompong ; Vanwong, Natchaya ; Atasilp, Chalirmporn ; Yodwongjane, Pavitchaya ; Jinda, Pimonpan ; Sirachainan, Ekaphop ; Puangpetch, Apichaya ; Chansriwong, Phichai ; Fabienne, Thomas ; Reungwetwattana, Thanyanan ; Chamnanphon, Monpat ; Aiempradit, Somthawin

DPYD polymorphisms have been widely found to be related to 5-FU-induced toxicities. The aim of this study was to establish significant associations between five single-nucleotide polymorphisms of DPYD and 5-FU hematological toxicities in Thai colorectal cancer patients. The toxicities were analyzed at the first and second cycles of 5-FU administration in 75 patients. Genotyping was performed using TaqMan real-time PCR. The genotype frequencies of DPYD*2A,1905 + 1 G > A and DPYD 1774 C > T were all wild type. The frequencies of genetic testing for DPYD*5, 1627 A > G, DPYD 1896T > C, and DPYD*9A, 85 A > G were 37.30% (AG; 34.60%, GG; 2.70%), 32.00% (TC; 25.30%, CC; 6.70%), and 13.40% (AG; 10.70%, GG; 2.70%), respectively. The results reveal significant findings with neutropenia occurring in 100% (2/2) of the patients with homozygous variant DPYD*9A (GG) from the first cycle of treatment for both Grade 1-4 and Grade 3-4 toxicities (P = 0.003 and P < 0.001 respectively). DPYD *9A was related to Grade 1-4 leukopenia (P = 0.001) and both Grade 1-4 and severe thrombocytopenia (P < 0.001 and P < 0.001) in the first cycle. In the second cycle, DPYD*5 was shown to be closely associated with no Grade 1-4 toxicity (P = 0.02). However, we found that 100% (2/2) of patients carrying the homozygous variant (GG) DPYD*5, presented no significant toxicity, so, DPYD*5 may be a predictive marker of neutropenia in patients treated with 5-FU. These outcomes suggest that there may be an increased risk of developing 5-FU-induced neutropenia in patients carrying the DPYD*9A, which should be considered as part of the standard procedure.

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)

Article

作者: Bet, Pierre M ; Boisdron-Celle, Michele ; van de Kerkhof, Daan ; van den Wildenberg, Sebastian A H ; Deenen, Maarten J ; Banken, Evi ; Moes, Dirk Jan A R ; Maring, Jan Gerard ; Hanrath, Maarten A ; Creemers, Geert-Jan M ; Bax, Ramon ; van Hellemond, Irene E G ; van den Bosch, Bianca J C

Abstract:

Purpose:

In 20–30% of the patients, fluoropyrimidines (5-FU) based chemotherapy leads to severe toxicity, which is associated with dihydropyridine dehydrogenase (DPD) deficiency. Therefore, DPYD genotyping became standard practice before treatment with fluoropyrimidines. Nevertheless, only 17% of the patients with severe toxicity have a DPYD variant. Therefore, an urgent need persists to investigate other strategies contributing to prediction and prevention of toxicity. Endogenous DPD substrates are considered as potential biomarkers to predict toxicity, yet contradictional data exist on demonstrating uracil as a reliable biomarker. Thymine as biomarker for toxicity has been investigated less. The aim of this study was to determine the association between the concentrations of uracil, thymine dihydrouracil (DHU) and dihydrothymine (DHT), with the systemic drug exposure of 5-FU and DPD enzyme activity in patients treated with 5-FU.

Methods:

We included 36 patients with gastrointestinal malignancy who received 5-FU infusion. DPYD genotyping was conducted before start of treatment. Blood samples for determining 5-FU, uracil and thymine concentrations during infusion and DPD enzyme activity were taken.

Results:

We found a significant correlation between the 5-FU systematic exposure and baseline thymine concentrations (R2 = 0.1468; p = 0.0402). DPD enzyme activity was significantly correlated with baseline thymine concentrations but no correlation was found between DPD enzyme activity and 5-FU systemic drug exposure.

Conclusion:

5-FU dose individualization based on thymine concentrations could be a promising addition to DPYD genotyping to predict 5-FU-induced toxicity. Larger prospective trials are needed to examine thymine as predictor for toxicity in daily practice.

Trial registration:

Trial NL7539 at ‘Overview of Medical Research in the Netherlands’ (ID NL-OMON21471). Date of registration 19-02-2019.

2025-12-01·Journal of Gastrointestinal Cancer

Retraction Note: Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil

Article

作者: Naghibzadeh, Niloufar ; Avan, Amir ; Khazaei, Majid ; Mostafapour, Asma ; Hashemzehi, Milad ; Hassanian, Seyed Mahdi ; Asgharzadeh, Fereshteh

1,616

项与氟尿嘧啶相关的新闻（医药）

2025-07-01

·ioncology

ESMO GI 2025明日启幕，中国消化道肿瘤前沿声音响彻巴塞罗那

编者按：2025年7月2日-5日，欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于西班牙巴塞罗那盛大召开，汇聚全球消化道领域最新诊疗观念与进展，包括704篇讲题和427篇壁报。此次会上，中国学者贡献了39项讲题，其中包括2项最新突破性摘要（LBA）、2项微型口头报告（MO）、1项教育主题汇报（Education Session）和34篇壁报（Poster）。现将中国之声整理如下，以飨读者。最新突破性摘要（LBA）摘要号：LBA1研究名称：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND TrialFIND试验中期分析：ctDNA甲基化动态监测指导非转移性结直肠癌术后随访讲者：彭俊杰 | 复旦大学附属肿瘤医院会场：Room Madrid时间：7月4日 16:30 - 16:40（当地时间）摘要号：LBA2研究名称：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)TALENTACE研究：比较按需TACE联合阿替利珠单抗+贝伐珠单抗(Atezo+Bev)与单纯按需TACE治疗未经系统治疗的中高肿瘤负荷不可切除肝细胞癌（uHCC）的III期开放标签随机对照研究讲者：韩国宏 | 西安国际医学中心医院会场：Room Barcelona时间：7月3日 14:50 - 15:00（当地时间）微型口头报告（Mini Oral）摘要号：149MO研究名称：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 StudyABSK-011-201研究II期最新结果：依帕戈替尼（ABSK-011）联合阿替利珠单抗用于FGF19过表达型晚期肝细胞癌（HCC）的一线治疗及用于经免疫检查点抑制剂（ICIs）治疗患者的疗效分析讲者：程琪 | 华中科技大学同济医学院附属同济医院会场：Room Barcelona时间：7月2日 17:15 - 17:20（当地时间）摘要号：150MO研究名称：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosisSIERRA研究IIIb期安全性分析：度伐利尤单抗（D）联合替西木单抗（T）一线治疗伴临床预后不良特征的肝细胞癌（HCC）患者讲者：Stephen L. Chan | 香港中文大学会场：Room Barcelona时间：7月2日 17:20 - 17:25（当地时间）教育专题会（Education Session）讲题：New medical treatment in 2025 beyond IO combinations2025年突破免疫联合疗法的新兴医学治疗方向讲者：Stephen L. Chan | 香港中文大学会场：Room Madrid时间：7月3日 12:00 - 12:20（当地时间）壁报（Poster）01结直肠癌摘要号：11P研究名称：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I StudyNALIRIFOX联合靶向治疗一线治疗转移性结直肠癌的I期研究讲者：Haojie Zhou | 复旦大学附属中山医院摘要号：49P研究名称：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer转移性结直肠癌一线诱导治疗后维持策略与治疗间歇的多中心倾向性评分匹配比较研究讲者：Ka Yan Lai | 伊利沙伯医院摘要号：65P研究名称：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal CancerBETTER研究：替雷利珠单抗+贝伐珠单抗+TAS102+SBRT三线治疗MSS/pMMR转移性结直肠癌的开放标签单臂试验讲者：张群 | 南京鼓楼医院摘要号：98P研究名称：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth一种预测早期结直肠癌浸润深度的整合分子标志物的新型风险分层模型讲者：Bing Li | 复旦大学附属中山医院摘要号：130eP研究名称：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer从循证到实践：MSS/MSI-L结直肠癌免疫治疗的多中心真实世界研究与Meta分析讲者：Yue T. Gou | 中南大学湘雅医院摘要号：131eP研究名称：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment贝伐珠单抗+奥沙利铂+伊立替康三联方案治疗氟尿嘧啶经治转移性结直肠癌的疗效与安全性讲者：韩璐 | 中国人民解放军总医院第五医学中心摘要号：139eP研究名称：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)中国结直肠癌MSI/MMR检测与治疗实践全国调研（SUMMER研究）讲者：王正航 | 北京大学肿瘤医院摘要号：146TiP研究名称：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progressMIRACLE3研究：依沃西单抗联合放化疗一线治疗MSS型不可切除肝/肺转移结直肠癌的II期试验（进行中）讲者：李心翔 | 复旦大学附属肿瘤医院摘要号：224P研究名称：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)SPRING-01研究：短程放疗序贯信迪利单抗+CAPOX全直肠新辅助治疗局部进展期直肠癌的前瞻性随机对照试验讲者：田锋 | 山东第一医科大学附属省立医院摘要号：226P研究名称：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results阿得贝利单抗+短程放疗+CAPOX全新辅助治疗pMMR局部进展期直肠癌的中期分析讲者：靖昌庆 | 山东第一医科大学附属省立医院摘要号：229P研究名称：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)高风险局部进展期直肠癌新辅助放化疗±FOLFOXIRI强化治疗的随机研究：临床与生存质量分析（NCT03997435）讲者：Ka Yan Lai | 伊利沙伯医院02肝胆胰肿瘤摘要号：157P研究名称：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analysesCheckMate 9DW研究拓展分析：纳武利尤单抗联合伊匹木单抗 vs 仑伐替尼或索拉非尼一线治疗中国不可切除/晚期肝细胞癌患者讲者：秦叔逵 | 中国药科大学附属南京天印山医院摘要号：183P研究名称：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population中性粒细胞-淋巴细胞比值（NLR）与PLR、LMR、SII、PNI在肝癌冷冻消融术患者中的预后价值比较及最佳适用人群探索讲者：李家平 | 中山大学附属第一医院摘要号：195P研究名称：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinomaCOVID-19、肝硬化与肝细胞癌关联机制的生物信息学与系统生物学研究讲者：Xianxiang Chen | 广西医科大学第一附属医院摘要号：203eP研究名称：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis基于cfDNA生物标志物与人工智能模型的肝癌早期筛查：系统评价与Meta分析讲者：Minh Le | 台北医学大学摘要号：206eP研究名称：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib基线ALBI分级对接受仑伐替尼治疗的肝细胞癌患者预后的影响讲者：商昌珍 | 中山大学孙逸仙纪念医院摘要号：209eP研究名称：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT MechanismRPL41通过转录因子RUNX2介导的上皮间质转化（EMT）机制促进肝细胞癌转移讲者：Zheng A. Hua | 重庆大学附属沙坪坝医院摘要号：302P研究名称：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer索凡替尼联合吉西他滨及白蛋白结合型紫杉醇用于可切除/临界可切除胰腺癌新辅助治疗讲者：高松 | 天津市肿瘤医院摘要号：313P研究名称：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancerABHD17C介导的BCL6B蛋白S-去棕榈酰化通过激活CD24转录抵抗胰腺癌巨噬细胞吞噬讲者：Yalu Zhang | 中国科学技术大学附属第一医院摘要号：317P研究名称：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity肿瘤微环境芯片：异质性下免疫治疗疗效的实时观测窗口讲者：Chiao-Min Lin | 台湾清华大学摘要号：358P研究名称：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study胆道癌根治术后辅助化疗方案的疗效比较：单中心回顾性队列研究讲者：Wen-Ying Lin | 台北荣民总医院03胃食管癌摘要号：394P研究名称：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials卡瑞利珠单抗为基础治疗食管鳞癌的反应性皮肤毛细血管内皮增生（RCCEP）：两项III期试验的合并分析讲者：骆卉妍 | 中山大学肿瘤防治中心摘要号：396P研究名称：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy卡博替尼联合阿替利珠单抗用于含铂化疗失败的复发/转移性食管鳞癌（R/M ESCC）患者：单臂II期研究讲者：Hung-Yang Kuo | 台湾大学医学院附设医院摘要号：399P研究名称：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic ReprogrammingARL5B通过ROCK1-SREBP1介导代谢重编程驱动食管鳞癌进展的机制研究讲者：Xinyue Ma | 山东大学齐鲁医院摘要号：418P研究名称：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study纳武利尤单抗一线治疗晚期胃/胃食管结合部腺癌的真实世界研究结局：多中心回顾性观察研究讲者：邱红 | 华中科技大学同济医学院附属同济医院摘要号：419P研究名称：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)SURPASS研究：中国晚期胃/胃食管结合部癌（GC/GEJC）真实世界治疗模式与生物标志物检测现状调研讲者：Rongrui Liu | 中国人民解放军总医院摘要号：424P研究名称：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study化疗（SOX）联合替雷利珠单抗治疗胃癌肝转移：一项多中心II期研究的首次报告讲者：康牧星 | 浙江大学医学院附属第二医院摘要号：430P研究名称：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical TrialCLDN18.2特异性CAR-T细胞（CT041）治疗胃癌的应答与耐药特征解析：I期临床试验探索性生物标志物分析讲者：彭浩欣 | 北京大学肿瘤医院摘要号：436P研究名称：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions肝切除改善原发性病灶切除的胃癌肝转移患者预后讲者：Yun Feng | 复旦大学附属肿瘤医院04其他摘要号：219eP研究名称：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study转移性胃肠间质瘤行肿瘤细胞减灭术的预后因素分析：一项回顾性队列研究讲者：Haidong Zhang | 四川大学华西医院摘要号：495P研究名称：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction初始剂量减量策略改善老年胃肠道肿瘤患者化疗耐受性的优化研究讲者：Wendy W. Chan | 香港玛丽医院摘要号：499P研究名称：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapyTACR1基因型与含奥氮平止吐方案防治化疗相关性呕吐的疗效关联研究讲者：Winnie Yeo | 香港中文大学摘要号：505eP研究名称：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers安罗替尼治疗贝伐珠单抗经治胃肠道肿瘤的真实世界疗效讲者：陈锦章 | 南方医科大学南方医院摘要号：506eP研究名称：Impact of CARG-Guided Dose Adjustment of Anticancer Therapy on Adverse Events in Chinese Elderly Cancer Patients: A Prospective Study基于CARG评估指导抗肿瘤治疗剂量调整对中国老年癌症患者不良事件的影响：前瞻性研究讲者：葛郁平 | 北京协和医院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期免疫疗法临床结果

2025-07-01

·今日头条

全球首创CLDN18.2靶向药-佐妥昔单抗联合疗法，开出中国首张处方

2025年6月27日，佐妥昔单抗联合含氟尿嘧啶类及铂类药物的治疗方案，在北京、广州、上海、四川等地医院开出首张处方。作为我国首个且目前唯一获批的Claudin18.2（CLDN18.2）靶向创新疗法，该方案正式落地临床，不仅为晚期胃癌患者带来延长生存期的新希望，更意味着曾被视为“难治之症”的晚期胃癌，如今有了更具针对性的治疗选择！全球首个CLDN18.2靶向药落地中国，填补晚期胃癌30年治疗空白！胃癌是中国癌症相关死亡的第三大病因，2022年导致超26万例患者死亡。由于早期症状隐匿，约60%的中国患者确诊时已进展至晚期，而晚期胃癌的治疗手段极为有限——我国晚期患者五年生存率仅9.1%，因此，临床迫切需要突破性疗法延缓疾病进展。尤其是CLDN18.2阳性且HER2阴性的晚期胃及胃食管交界处癌患者，长期面临治疗选择匮乏、生存预后差的困境。而，佐妥昔单抗（Zolbetuximab，Vyloy®，威络益®）作为全球首个获批的CLDN18.2靶向IgG1单克隆抗体，为这类难治性患者带来了长生存的新希望。 2024年12月25日，国家药监局批准其联合氟尿嘧啶类及铂类化疗，用于一线治疗CLDN18.2阳性、HER2阴性的局部晚期不可切除或转移性胃/胃食管交界处腺癌，填补了这一领域的治疗空白。佐妥昔单抗重塑胃癌生存曲线：中位总生存期超1年，无进展生存超9个月全球知名期刊《新英格兰医学杂志》曾报道过“佐妥昔单抗（Zolbetuximab）治疗胃腺癌或胃食管连接部腺癌”的相关研究数据。该研究共入组1,072例胃腺癌或胃食管连接部腺癌患者，随机分为佐妥昔单抗组（537例）、安慰剂组（535例）。结果显示：佐妥昔单抗组中位总生存期（OS）为16.4个月，较安慰剂组的13.7个月显著延长（95%CI：0.67～0.89，详见下图B）。中位无进展生存期（PFS）分别为9.2个月（佐妥昔单抗组） vs 8.2个月（安慰剂组，95%CI：0.61～0.83，详见下图A），两项关键指标均展现出显著临床获益。 ▲图源“N Engl J Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除小编寄语根据上述的研究数据，对于HER2阴性、局部晚期不可切除或转移性胃或胃食管连接部腺癌且肿瘤为 claudin 18.2阳性的患者，佐妥昔单抗联合化疗可延长无进展生存期和总生存期，优于安慰剂联合化疗，且未观察到严重不良反应。未来，我们有望看到更多高效、低毒的CLDN18.2靶向治疗药物问世，并且在联合治疗模式的探索上取得更大突破，从而显著提高胃癌患者的治疗效果，改善患者的生存质量和预后，为胃癌的攻克迈出坚实的一步。想了解胃癌更多靶向药的患者，可将治疗经历、近期病理报告、基因检查结果等，提交至全球肿瘤医生网医学部，初步评估或了解详细的入排标准。参考资料 [1]Shitara K,et al.Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma[J]. New England Journal of Medicine, 2024, 391(12): 1159-1162. https://www-nejm-org.libproxy1.nus.edu.sg/doi/full/10.1056/NEJMc2409512#ap2 [2]https://m.bjnews.com.cn/detail/1751017933168712.html 本文为全球肿瘤医生网原创，未经授权严禁转载

突破性疗法临床结果临床研究

2025-07-01

·肿瘤界

2025 ESMO GI | 中国智慧闪耀国际：入选研究一览

点击蓝字关注我们前言一年一度的欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于2025年7月2日~5日在巴塞罗那召开。日前，大会官网披露了摘要标题，其中34项中国研究入选。整理如下，和您一起先睹为快！胃食管癌1摘要号：394P研究名称（英文）：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials 讲者：骆卉妍 | 中山大学肿瘤防治中心2摘要号：396P研究名称（英文）：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy 讲者：Hung-Yang Kuo | 台湾大学医学院附设医院3摘要号：399P研究名称（英文）：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic Reprogramming 讲者：Xinyue Ma | 山东大学齐鲁医院4摘要号：418P研究名称（英文）：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study 讲者：邱红 | 华中科技大学同济医学院附属同济医院5摘要号：419P研究名称（英文）：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)讲者：Rongrui Liu | 中国人民解放军总医院6摘要号：424P研究名称（英文）：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study 讲者：康牧星 | 浙江大学医学院附属第二医院7摘要号：430P研究名称（英文）：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial 讲者：彭昊昕 | 北京大学肿瘤医院8摘要号：436P研究名称（英文）：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions讲者：Yun Feng | 复旦大学附属肿瘤医院肝胆胰肿瘤1摘要号：LBA2研究名称（英文）：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) 讲者：韩国宏 | 西安国际医学中心医院2摘要号：149MO研究名称（英文）：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study讲者：程琪 | 华中科技大学同济医学院附属同济医院3摘要号：150MO研究名称（英文）：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis讲者：Stephen L. Chan | 香港中文大学4摘要号：157P研究名称（英文）：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses 讲者：秦叔逵 | 中国药科大学附属南京天印山医院5摘要号：183P研究名称（英文）：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population讲者：李家平 | 中山大学附属第一医院6摘要号：195P研究名称（英文）：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma讲者：Xianxiang Chen | 广西医科大学第一附属医院7摘要号：203eP研究名称（英文）：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis讲者：Minh Le | 台北医学大学8摘要号：206eP研究名称（英文）：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib讲者：商昌珍 | 中山大学孙逸仙纪念医院9摘要号：209eP研究名称（英文）：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism讲者：Zheng Hua | 重庆大学附属沙坪坝医院10摘要号：302P研究名称（英文）：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer讲者：高松 | 天津市肿瘤医院11摘要号：313P研究名称（英文）：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer讲者：Yalu Zhang | 中国科学技术大学附属第一医院12摘要号：317P研究名称（英文）：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity讲者：Chiao-Min Lin | 台湾清华大学13摘要号：358P研究名称（英文）：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study讲者：Wen-Ying Lin | 台北荣民总医院结直肠癌1摘要号：LBA1研究名称（英文）：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND Trial讲者：彭俊杰 | 复旦大学附属肿瘤医院2摘要号：11P研究名称（英文）：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study讲者：Haojie Zhou | 复旦大学附属中山医院3摘要号：49P研究名称（英文）：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer讲者：Connie Ka Yan Lai | 伊利沙伯医院4摘要号：65P研究名称（英文）：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer 讲者：张群 | 南京鼓楼医院5摘要号：98P研究名称（英文）：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth讲者：Bing Li | 复旦大学6摘要号：130eP研究名称（英文）：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer讲者：Yue Gou | 中南大学7摘要号：131eP研究名称（英文）：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment讲者：韩璐 | 中国人民解放军总医院第五医学中心8摘要号：139eP研究名称（英文）：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)讲者：王正航 | 北京大学肿瘤医院9摘要号：146TiP研究名称（英文）：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress讲者：李心翔 | 复旦大学附属肿瘤医院10摘要号：224P研究名称（英文）：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)讲者：Feng Tian | 山东第一医科大学附属省立医院11摘要号：226P研究名称（英文）：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results讲者：靖昌庆 | 山东第一医科大学附属省立医院12摘要号：229P研究名称（英文）：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)讲者：Ka Yan Lai | 伊利沙伯医院胃肠道罕见肿瘤1摘要号：219eP研究名称（英文）：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study 讲者：Haidong Zhang | 四川大学华西医院其他1摘要号：495P研究名称（英文）：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction讲者：Wendy W. Chan | 香港大学李嘉诚医学院2摘要号：499P研究名称（英文）：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy讲者：Winnie Yeo | 香港中文大学3摘要号：505eP研究名称（英文）：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers讲者：陈锦章 | 南方医科大学南方医院备注：如有遗漏或任何问题，请给我们留言~声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通消化系统肿瘤编辑：lagertha审核：南星

临床结果细胞疗法临床2期免疫疗法

100 项与氟尿嘧啶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00584	氟尿嘧啶	L01BC02	DB00544

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
食管癌	日本	Kyowa Kirin Co., Ltd.	2021-11-25
肠肿瘤	日本	Kyowa Kirin Co., Ltd.	2018-09-21
头颈部肿瘤	日本	Kyowa Kirin Co., Ltd.	2005-02-14
鲍恩病	澳大利亚	iNova Pharmaceuticals (Australia) Pty Ltd.	1991-08-23
肿瘤	中国	远大医药（中国）有限公司	1981-01-01
皮肤肿瘤	日本	Kyowa Kirin Co., Ltd.	1972-08-26
光化性角化病	美国	Extrovis AG	1970-07-29
晚期胃癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
子宫内膜癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
肝癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
肺癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
卵巢癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
复发性胃癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
胃癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
宫颈癌	日本	Kyowa Kirin Co., Ltd.	1967-07-24
乳腺癌	美国	Spectrum Pharmaceuticals, Inc.	1962-04-25
结直肠癌	美国	Spectrum Pharmaceuticals, Inc.	1962-04-25
胰腺癌	美国	Spectrum Pharmaceuticals, Inc.	1962-04-25
胃腺癌	美国	Spectrum Pharmaceuticals, Inc.	1962-04-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
RAS/BRAF基因野生型结直肠癌	临床3期	意大利	National Cancer Institute	2024-06-12
皮肤鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
转移性头颈部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
喉鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
口腔鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
晚期胃食管交界处腺癌	临床3期	美国	Alliance for Clinical Trials in Oncology	2023-01-31
晚期胃食管交界处腺癌	临床3期	波多黎各	Alliance for Clinical Trials in Oncology	2023-01-31
转移性胃食管腺癌	临床3期	美国	Alliance for Clinical Trials in Oncology	2023-01-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04554836 (CTgov)	临床2期	直肠腺癌 \| RAS 突变结直肠癌 \| 结肠癌	6	Cetuximab+Leucovorin Calcium+Irinotecan Hydrochloride+Fluorouracil (FOLFIRI + Cetuximab)	鬱艱鑰艱鹹構繭鑰遞構 = 廠獵衊獵餘壓簾遞襯蓋衊鹹簾膚餘餘積餘夢願 (襯簾願網築艱蓋醖齋蓋, 蓋膚築積觸簾選選顧築 ~ 鹹壓淵選糧鏇壓衊餘齋) 更多	-	2025-06-08
				Leucovorin Calcium+Irinotecan Hydrochloride+Fluorouracil (FOLFIRI)	鬱艱鑰艱鹹構繭鑰遞構 = 夢夢糧憲餘鹽範壓窪願衊鹹簾膚餘餘積餘夢願 (襯簾願網築艱蓋醖齋蓋, 窪築願憲鏇網艱簾壓窪 ~ 醖衊窪遞顧襯鹽製壓構) 更多
NCT04617457 (HOLIPANC, ASCO2025) 人工标引	临床2期	胰腺癌新辅助	56	Nal-IRIFOX (liposomal irinotecan, oxaliplatin, 5-fluorouracil/folinic acid)	夢構淵繭構衊網顧獵鹽(築築憲鬱廠選壓鹽製齋) = 鹽餘淵糧鹹築獵艱網夢選顧齋夢顧夢遞膚鬱網 (廠鏇艱廠顧蓋餘壓積廠 ) 更多	积极	2025-05-30
ASCO2025	N/A	二线	26	Cisplatin plus high dose infusional 5-fluorouracil and leucovorin (P-HDFL)	簾醖顧繭鹽襯願選壓鹹(齋艱遞遞網繭簾築鹽餘) = 選繭遞選獵網襯糧繭鹹積顧淵選廠獵艱衊構網 (廠蓋繭繭築獵製醖鹹範 ) 更多	积极	2025-05-30
ASCO2025	N/A	口腔肿瘤	-	5-fluorouracil/Curcumin Nanoemulsion	窪鹽願製遞範範鏇網衊(顧製襯觸蓋餘願鑰膚齋) = as 5-FU/Cur -NE concentration rises, Bcl-2 was gradually down regulated (80% reduced expression at 100nm), indicating effective anti-cancer properties 壓繭齋窪鏇築獵廠鬱襯 (簾憲顧簾鑰憲淵淵蓋廠 ) 更多	积极	2025-05-30
ASCO2025	N/A	复发性头颈部鳞状细胞癌一线	48	Tegafur-Uracil	廠齋築壓鏇壓廠觸鏇觸(淵範構衊願構壓構艱襯) = 遞獵願壓構構築鬱積壓餘襯憲鏇獵選簾願獵艱 (鏇鏇艱遞願獵鹹顧齋構 ) 更多	积极	2025-05-30
ASCO2025	N/A	转移性腺癌一线	123	FOLFIRINOX	繭憲膚觸夢鹽選廠鏇鬱(範鏇範鹽獵遞鏇膚網廠) = 鏇簾鬱鑰鏇網網構鏇鬱蓋願積醖憲膚製醖觸鑰 (築廠餘選鹽鏇積膚願壓, 10.6 ~ 14.4) 更多	积极	2025-05-30
				Fluorouracil-based chemotherapy	繭憲膚觸夢鹽選廠鏇鬱(範鏇範鹽獵遞鏇膚網廠) = 餘願膚衊鹹鑰製襯範繭蓋願積醖憲膚製醖觸鑰 (築廠餘選鹽鏇積膚願壓, 10.6 ~ 14.4) 更多
NCT03944915 (DEPEND, CTgov)	临床2期	乳头状瘤病毒感染 \| HPV相关鳞状细胞癌 \| 局部晚期头颈部鳞状细胞癌	35	Nivolumab+Carboplatin+Paclitaxel (Standard Chemotherapy)	鏇憲構鏇構淵願築夢遞 = 觸遞網積齋網鏇憲蓋繭鑰衊繭壓夢蓋膚選醖範 (鏇衊鹹網艱鬱積獵網觸, 繭淵製蓋艱齋鹽顧鏇醖 ~ 餘鬱淵鑰獵獵鑰積窪顧) 更多	-	2025-05-11
				Radiation+Filgrastim Injection+Paclitaxel+Hydroxyurea Pill+cisplatin+5-fluorouracil (De-escalated Chemotherapy)	鏇憲構鏇構淵願築夢遞 = 餘鏇廠築鹽餘鏇廠餘衊鑰衊繭壓夢蓋膚選醖範 (鏇衊鹹網艱鬱積獵網觸, 憲糧廠衊鏇廠衊糧憲範 ~ 網鏇襯觸鏇鑰憲醖鏇築) 更多
NCT02246127 (SEQTOR \| GETNE-1206, CTgov)	临床3期	晚期胰腺神经内分泌肿瘤	141	STREPTOZOCIN+Drug: Everolimus+FLUOROURACIL (Sequence A, Drug: Everolimus First)	選獵鏇壓鏇願艱顧觸觸 = 遞淵夢壓鏇簾夢夢鏇鬱餘顧選鏇淵鏇製齋夢願 (鏇壓鬱壓範積網艱糧鏇, 鹹獵艱窪餘蓋壓鏇觸選 ~ 築簾選範艱鑰獵繭壓齋) 更多	-	2025-05-11
				STREPTOZOCIN+Drug: Everolimus+FLUOROURACIL (Sequence B, Drug: STZ - 5FU First)	選獵鏇壓鏇願艱顧觸觸 = 顧製夢鹽餘簾餘淵蓋觸餘顧選鏇淵鏇製齋夢願 (鏇壓鬱壓範積網艱糧鏇, 廠夢積構齋艱構膚築憲 ~ 齋餘衊積繭夢網蓋淵選) 更多
NCT03107182 (OPTIMA II \| OPTIMA-II, CTgov)	临床2期	头颈部鳞状细胞癌 \| HPV阳性的口咽鳞状细胞癌 \| HPV相关鳞状细胞癌 ... 更多	72	Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA))	艱簾獵艱製夢糧鹹鬱餘 = 廠遞壓鑰壓繭遞壓遞淵繭齋膚鹹獵壓齋壓壓齋 (選顧鑰醖齋製網築鹽鬱, 願壓夢觸範衊顧淵襯齋 ~ 窪選窪鬱築鑰積選構糧) 更多	-	2025-05-06
				Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA))	艱簾獵艱製夢糧鹹鬱餘 = 窪鹽鏇鏇衊積獵範齋憲繭齋膚鹹獵壓齋壓壓齋 (選顧鑰醖齋製網築鹽鬱, 餘鹽觸壓鬱醖醖鬱獵壓 ~ 憲積襯鹽夢淵選淵構窪) 更多
NCT04068103 (NRG-GI005 (COBRA), CTgov)	临床2/3期	大肠腺癌 \| 结肠癌	635	Patient Observation (Arm I (Blood Stored and Tested for ctDNA Later))	鏇願網蓋醖鏇夢夢憲鏇: P-Value = 0.98	-	2025-04-27
				Patient Observation+Leucovorin+oxaliplatin+Capecitabine+Fluorouracil (Arm II (Blood Tested for ctDNA at Baseline))